ArticleBMC global and public health2026
Effectiveness of mobile vaccination teams to increase COVID-19 booster uptake in Singapore: a population-based synthetic control study.
Article in BMC global and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sociodemographic and Health-Risk Determinants of COVID-19 Vaccine Booster Preferences and Willingness to Pay in Singapore: Discrete Choice Experiment.Interactive journal of medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMobile vaccination teams (MVTs) have been deployed to improve access to COVID-19 vaccination in the community, but it remains largely uncertain how effective MVTs are at increasing uptake of COVID-19 booster vaccination, particularly in densely populated urban areas with pre-existing access to healthcare facilities. This study leveraged large-scale administrative databases to estimate the population-level effectiveness and public health impact of MVTs in increasing first and second COVID-19 booster vaccination uptake in an urbanised city-state with high population density and high pre-existing uptake of primary vaccination against COVID-19.
methodsIn this synthetic control study, we used national vaccination databases in Singapore to evaluate if MVTs deployed from 19 January 2022 to 14 January 2024 increased the number of first/second COVID-19 booster doses across 190 and 114 locations comprising 287,216 and 373,940 eligible residents, respectively. In January 2022, 84.49% of the eligible population had received their first booster dose which was rolled out on 14 September 2021; the second booster dose was rolled out on 22 April 2022. To evaluate the effectiveness of the MVT intervention, we used the synthetic control method to generate appropriate counterfactuals for intervention locations using a weighted combination of 15,200 and 9,120 corresponding sites (without MVT intervention) comprising 11,948,807 and 15,414,890 residents, for comparison of first/second COVID-19 booster uptake, respectively.
resultsMVT interventions were associated with a 24.35% (95% confidence intervals [CI]: 15.00%-35.45%) and a 182.68% (95% CI: 154.60%-218.56%) increase in first and second booster uptake, respectively, with approximately 2,832 (95% CI: 1,809-3,846) first booster doses and 5,347 (95% CI: 5,017-5,687) second booster doses attributable to MVT interventions. Subgroup analysis showed that these effectiveness estimates were replicated across most subgroups (age/sex/ethnicity). Intervention effectiveness estimates were larger in subpopulations which may have challenges accessing immunisation centres.
conclusionsMVTs increased vaccination uptake during COVID-19 endemicity by improving geographical accessibility, even in the context of a densely populated urban setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.